EXPRESSION AND FUNCTIONAL ACTIVITY OF BREAST CANCER RESISTANCE PROTEIN (BCRP, ABCG2) TRANSPORTER IN THE HUMAN CHORIOCARCINOMA CELL LINE BEWO

1 Breast cancer resistance protein (BCRP, ABCG2) is a drug efflux transporter that is believed to affect the drug disposition of several drugs and xenobiotics. In the present study, we evaluated the localization and functional expression of BCRP in the human choriocarcinoma cell line BeWo, an in vitro model of the human trophoblast, and compared it with the expression of P‐glycoprotein (MDR1, ABCB1) as the most widely studied placental transporter. In addition, the expression of BCRP at the mRNA level was compared with that of MDR1 in the human term placenta. 2 Western blotting analysis revealed high endogenous expression of BCRP protein in BeWo cells. Using indirect immunofluorescence microscopy, we found that the BCRP transporter appears to be localized predominantly at the apical plasma membrane. Functional studies showed a significant effect of the BCRP inhibitors GF120918 (5 mmol/L) and Ko143 (1 mmol/L) on mitoxantrone accumulation and, thus, confirmed efflux activity of BCRP in BeWo cells. 3 Using absolute mRNA quantification with real‐time reverse transcription–polymerase chain reaction, we found high expression of BCRP in BeWo cells, whereas no transcript of MDR1 (P‐glycoprotein), the most extensively studied drug transporter, was detected. 4 In the human placenta, BCRP was localized predominantly in the syncytiotrophoblast layer; however, immunopositivity for the BXP‐21 antibody was also observed in fetal vessels of the chorionic villi. The number of BCRP transcripts in the human term placenta was found to be more than 10‐fold higher compared with the expression of MDR1. 5 In conclusion, we suggest that BeWo cells could serve as a suitable in vitro model to study trans‐trophoblast transport of BCRP substrates and that placental BCRP can play an important role in preventing the accumulation of potentially toxic xenobiotics in the trophoblast cells.

[1]  L. Doyle,et al.  Promoter characterization and genomic organization of the human breast cancer resistance protein (ATP-binding cassette transporter G2) gene. , 2001, Biochimica et biophysica acta.

[2]  A. van der Ende,et al.  Iron metabolism in BeWo chorion carcinoma cells. Transferrin-mediated uptake and release of iron. , 1987, The Journal of biological chemistry.

[3]  R. Pattillo,et al.  The establishment of a cell line of human hormone-synthesizing trophoblastic cells in vitro. , 1968, Cancer research.

[4]  A. Schinkel,et al.  Multidrug resistance and pharmacological protection mediated by the breast cancer resistance protein (BCRP/ABCG2). , 2002, Molecular cancer therapeutics.

[5]  Alfred H. Schinkel,et al.  Human Breast Cancer Resistance Protein: Interactions with Steroid Drugs, Hormones, the Dietary Carcinogen 2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridine, and Transport of Cimetidine , 2005, Journal of Pharmacology and Experimental Therapeutics.

[6]  Y. Sawada,et al.  Uptake mechanism of valproic acid in human placental choriocarcinoma cell line (BeWo). , 2001, European journal of pharmacology.

[7]  I. Ellinger,et al.  IgG transport across trophoblast‐derived BeWo cells: a model system to study IgG transport in the placenta , 1999, European journal of immunology.

[8]  K. Audus,et al.  Novel Organic Cation Transporter 2-Mediated Carnitine Uptake in Placental Choriocarcinoma (BeWo) Cells , 2005, Journal of Pharmacology and Experimental Therapeutics.

[9]  N. Illsley,et al.  Transepithelial glucose transport and metabolism in BeWo choriocarcinoma cells. , 2002, Placenta.

[10]  B. Sarkadi,et al.  ABCG2 – a transporter for all seasons , 2004, FEBS letters.

[11]  B. M. Eaton,et al.  Sequential preparation of highly purified microvillous and basal syncytiotrophoblast membranes in substantial yield from a single term human placenta: inhibition of microvillous alkaline phosphatase activity by EDTA. , 1994, Biochimica et biophysica acta.

[12]  Torben Skovsgaard,et al.  Use of peptide antibodies to probe for the mitoxantrone resistance-associated protein MXR/BCRP/ABCP/ABCG2. , 2002, Biochimica et biophysica acta.

[13]  Martin Kopecky,et al.  P-glycoprotein expression and distribution in the rat placenta during pregnancy. , 2004, Reproductive toxicology.

[14]  J. Schellens,et al.  Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. , 2002, Molecular cancer therapeutics.

[15]  Jashvant D Unadkat,et al.  Placental drug transporters. , 2004, Current drug metabolism.

[16]  M. Lisanti,et al.  Polarized apical distribution of glycosyl-phosphatidylinositol-anchored proteins in a renal epithelial cell line. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[17]  K. Audus,et al.  Functional expression of P-glycoprotein in primary cultures of human cytotrophoblasts and BeWo cells. , 2000, Reproductive toxicology.

[18]  L. Doyle,et al.  Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2) , 2003, Oncogene.

[19]  A. van der Ende,et al.  Apical and basolateral transferrin receptors in polarized BeWo cells recycle through separate endosomes , 1991, The Journal of cell biology.

[20]  Donald W. Miller,et al.  In vitro and in vivo models for assessing drug efflux transporter activity. , 2003, Advanced drug delivery reviews.

[21]  G. Strous,et al.  Iron Metabolism in BeWo Chorion Carcinoma Cells , 1987 .

[22]  I. Ellinger,et al.  Placental Alkaline Phosphatase Expression at the Apical and Basal Plasma Membrane in Term Villous Trophoblasts , 2001, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[23]  J. Schellens,et al.  Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. , 2000, Journal of the National Cancer Institute.

[24]  H Nakano,et al.  Human placental transport of vinblastine, vincristine, digoxin and progesterone: contribution of P-glycoprotein. , 2000, European journal of pharmacology.

[25]  M. J. van de Vijver,et al.  Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. , 2001, Cancer research.

[26]  L. Huber,et al.  The recycling endosome of Madin-Darby canine kidney cells is a mildly acidic compartment rich in raft components. , 2000, Molecular biology of the cell.

[27]  W. T. Beck,et al.  Modulation of breast cancer resistance protein (BCRP/ABCG2) gene expression using RNA interference. , 2004, Molecular cancer therapeutics.

[28]  T. Litman,et al.  Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR. , 1999, Cancer letters.

[29]  M. V. St-Pierre,et al.  Mechanisms of drug transfer across the human placenta-a workshop report. , 2002, Placenta.

[30]  B. Hirst,et al.  Epithelial secretion of vinblastine by human intestinal adenocarcinoma cell (HCT-8 and T84) layers expressing P-glycoprotein. , 1991, British Journal of Cancer.

[31]  Vincenzo,et al.  A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. , 1998, Cancer research.

[32]  C. Sibley,et al.  Role of MDR1 and MRP1 in trophoblast cells, elucidated using retroviral gene transfer. , 2003, American journal of physiology. Cell physiology.

[33]  J. Noordhoek,et al.  Mechanisms of drug transfer across the human placenta. , 1998, Pharmacy World and Science.

[34]  P. Pávek,et al.  Breast cancer resistance protein (BCRP/ABCG2). , 2005, The international journal of biochemistry & cell biology.

[35]  W. El-Deiry.  Phenomenology and Scientific Progress , 2002, Cancer biology & therapy.

[36]  A. Pardee.  Role Reversal for Anticancer Agents , 2002, Cancer biology & therapy.

[37]  N. Illsley,et al.  Simultaneous preparation of paired, syncytial, microvillous and basal membranes from human placenta. , 1990, Biochimica et biophysica acta.

[38]  K. Mostov,et al.  Apical and Basolateral Endocytic Pathways of MDCK Cells Meet in Acidic Common Endosomes Distinct from a Nearly‐Neutral Apical Recycling Endosome , 2000, Traffic.

[39]  I. Pastan,et al.  Isolation and sequence of the promoter region of the human multidrug-resistance (P-glycoprotein) gene. , 1987, The Journal of biological chemistry.

[40]  T. Litman,et al.  A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2). , 2001, Biochimica et biophysica acta.

[41]  K. Audus,et al.  Efflux transporters of the human placenta. , 2003, Advanced drug delivery reviews.

[42]  L. Doyle,et al.  A multidrug resistance transporter from human MCF-7 breast cancer cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[43]  K. Ueda,et al.  Heat‐shock responsive elements in the induction of the multidrug resistance gene (MDR1) , 1992, FEBS letters.

[44]  Manpreet Singh,et al.  Workshop Report , 2005, IPTPS.

[45]  Sastry.  Techniques to study human placental transport. , 1999, Advanced drug delivery reviews.

[46]  T. Thalhammer,et al.  Inhibition of P-glycoprotein-mediated vinblastine transport across HCT-8 intestinal carcinoma monolayers by verapamil, cyclosporine A and SDZ PSC 833 in dependence on extracellular pH , 2004, Cancer Chemotherapy and Pharmacology.